Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
9.97
+1.09 (12.27%)
At close: Sep 17, 2025, 4:00 PM EDT
9.97
0.00 (0.00%)
After-hours: Sep 17, 2025, 4:04 PM EDT
Valneva SE Revenue
Valneva SE had revenue of 48.33M EUR in the quarter ending June 30, 2025, with 26.98% growth. This brings the company's revenue in the last twelve months to 196.33M, up 25.47% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
196.33M EUR
Revenue Growth
+25.47%
P/S Ratio
3.71
Revenue / Employee
275,353 EUR
Employees
713
Market Cap
854.68M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VALN News
- 14 days ago - Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate - GlobeNewsWire
- 23 days ago - Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday - Benzinga
- 23 days ago - Johnson Fistel Investigates Valneva Following FDA Suspension - GlobeNewsWire
- 23 days ago - Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US - Benzinga
- 23 days ago - FDA suspends Valneva's chikungunya vaccine license in the U.S. - Reuters
- 23 days ago - Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. - GlobeNewsWire
- 4 weeks ago - Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older - GlobeNewsWire
- 5 weeks ago - Valneva SE (VALN) Q2 2025 Earnings Call Transcript - Seeking Alpha